Simplicity (insulin pen for diabetics)

2022: Wearable insulin pen for diabetics released

In early July 2022, CeQur introduced the Simplicity device, which is designed to make insulin administration as convenient as possible for people with diabetes. The company strives to make insulin therapy as convenient as possible, especially for those patients who prefer to independently manage insulin delivery.

A wearable disposable bolus insulin administration system, Simplicity, was developed as a wearable insulin pen. In early 2021, CeQur began a pilot commercial launch of the FDA-certified and CE-labeled device, which did not end until June 2022, and the company is now embarking on the next stage of limited release to the market. In April 2022, CeQur raised $115 million to support this launch and expand production.

Wearable insulin pen for diabetics released

The Simplicity device worn within three days is filled by the patient with Humalog or Novolog. After three days of wearing, the user gets rid of the device, fills another and places it on the stomach. The device holds 200 units of insulin and, thanks to two small buttons on each side, each pressing of the button provides the introduction of two units.

Among the features of Simplicity, fewer painful injections, less hassle during meals, improved glucose control, increased adherence, better time in the range and more, according to the developers of the device. While the current technology offers a potentially fundamentally new way to manage insulin, there are still things CeQur could do in the future. This may include dosing in different steps and wear times that last more than three days.

Paddock said the company is also surprised by the fact that a third of the 1.5 thousand patients using Simplicity today are among the group of type 1 diabetes patients, although there may be a tendency to automate insulin delivery in this area. For those on the recipients "side, virtually nothing will change, CeQur CEO Brad Paddock said. Paddock said that the company is also surprised by the fact that a third of the 1.5 thousand patients using Simplicity as of July 4, 2022 belong to the group of type 1 diabetes patients, although there may be a tendency to automated insulin delivery in this area. The company sees Simplicity as a consumer-oriented product, Paddock said, and testing ads aimed directly at the consumer has proven very effective in attracting patient interest.^[1]

Notes